|Bid||15.95 x 800|
|Ask||16.29 x 1000|
|Day's Range||16.20 - 16.23|
|52 Week Range||11.80 - 33.28|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.50|
Aptorum Group Limited (APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of two preclinical drug candidates which target obesity and neuroblastoma, respectively. Under the recently-announced microbiota modulation platform operated by Aptorum Group’s wholly-owned subsidiary Claves Life Sciences Limited, we have commenced the preclinical development of macromolecule candidate CLS-1 targeting the treatment of obesity.
Aptorum Group Limited , a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today provided a business update and announced financial results for the six months ended June 30, 2019.
Aptorum Group Limited (APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces that it has initiated investigational new drug (IND)-enabling studies for ALS-4, a small drug molecule candidate indicated for the treatment of infections caused by Staphylococcus aureus (or “S. aureus”) including methicillin-resistant Staphylococcus aureus (MRSA, i.e., one of the commonly known “super-bugs”) based on a novel anti-virulence approach. ALS-4 development is on track and the company targets to submit the related IND in the first half year of 2020 and a hybrid Phase 1 clinical study is currently planned in North America with both healthy volunteers and patients to obtain preliminary efficacy readout.
Aptorum Group Limited (APM) went public through an initial public offering which closed in December 2018 and raised $12.0M (gross) from the sale of 761k common shares. The shares were added to the Morgan Stanley Capital International (MSCI) Hong Kong Micro Cap Index in May 2019. Aptorum is a Hong Kong based pre-revenue company focused on the development and eventual commercialization of a range of therapeutics in neurology, infectious diseases, gastroenterology, oncology and other disease areas.
Aptorum Group Limited (APM) (“the Company”) a pharmaceutical company dedicated to developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs, announced today the Company’s addition to the Morgan Stanley Capital International MSCI (“MSCI”) Hong Kong Micro Cap Index, effective Tuesday, May 28, 2019, Hong Kong Time. MSCI Hong Kong Micro Cap Index is an international equity benchmark recognized by institutional investors. Founder and Chief Executive Officer of Aptorum Group and Mr. Ian Huen commented “We are honoured to be added as a constituent stock of the MSCI Hong Kong Micro Cap Index.
Opportunity to invest in one of the most vibrant real estate sectors in the U.S. that is currently not available in most of the Asia Pacific countries. Aeneas Capital Limited (“ACL”) and Pyrinas Real Estate Management Limited (“Pyrinas”), based in Hong Kong, is launching a US$120m innovative closed-ended property fund – Pyrinas US Healthcare Real Estate Fund 1 SP – with a geographical focus on selected cities across North America.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Aptorum Group Limited (NASDAQ:APM) should be aware of the most powerful shareholder...
Claves Life Sciences Limited, a wholly owned subsidiary of Aptorum Group Limited ("Aptorum") (APM), is excited to announce the establishment of a novel therapeutic platform for the treatment of various diseases via modulation of the chemical signaling relating to gut microbiota. The role of gut microbiota in the pathogenesis of various diseases has been under the spotlight recently. It has been demonstrated that gut microbiota is related to major diseases such as metabolic and cardiovascular diseases1,2, cancer3, neurodegenerative diseases4, etc.
NEW YORK, April 30, 2019 -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on Aptorum Group Limited (NasdaqGM: APM).
Aptorum Group Limited (APM), Aeneas Capital Limited, and A*ccelerate Technologies Pte Ltd, the enterprise office of the Agency for Science, Technology and Research (A*STAR), have signed a USD$90 million agreement to co-create local deep tech start-ups in the healthcare and life sciences sector. This agreement, is the latest in a series of venture co-creation (VCC) agreements signed by A*ccelerate to strengthen the start-up ecosystem in Singapore. Through this agreement, Aptorum Group and A*ccelerate are looking at creating up to 20 deep tech ventures in Singapore over the next five years.
Aptorum Group Limited (APM) is excited to announce the launch and issuance of its asset backed Smart Pharma Token (“SMPT”) by its wholly owned subsidiary group, Smart Pharma group and Smart Pharmaceutical Limited Partnership (“SPLP”) targeted in May 2019. SPLP is extremely pleased to have jointly developed the SMPT token with Aenco, an affiliated blockchain development company focused on applications in the healthcare and financial sector. The SMPT token, an ERC-1404 security compliant token, is a unique token that tokenizes valuable pharmaceutical drugs and their underlying intellectual property and associated allocation of cash flows induced by continual product development and commercialization.
Aptorum Group Limited (APM) today announced the establishment of a new subsidiary group, Smart Pharma (“SmartP”), which operates its novel computational repurposed drug discovery, modeling and validation platform, together referred to as the “Smart-ACTTM” platform. Smart-ACTTM stands for Accelerated Commercialization of Therapeutics and encompasses state-of-the-art technology in systematic screening of existing approved drug molecules against selected therapeutic targets. Specifically, the Smart-ACTTM platform comprises of a network of modules and processes that simulate the effectiveness of drug molecules against diseases for outcome prediction and selection.
Aptorum Group Limited (APM) (“Aptorum” or the “Company”), a pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic technologies to tackle unmet medical needs, announced today that the Company, in a privately-negotiated transaction, repurchased all outstanding US$13,500,000 in aggregate principal amount of the 8.00 per cent. convertible bonds due 2019 (“Convertible Bonds”) from Peace Range Limited, a wholly owned subsidiary of Adamas Ping An Opportunities Fund LP, together with certain subscription right to subscribe up to the principal amount of the Bond at a US$12.17 (subject to adjustment) on or before December 17, 2019 (“Subscription Right”). The total consideration of the repurchase of the Convertible Bonds and the Subscription Right was US$13.6 million in cash, excluding accrued interest.
Aptorum Group Ltd. , a preclinical stage pharmaceutical company developing and commercializing a broad portfolio of projects under development of therapeutic and diagnostic technologies to tackle unmet medical needs, today provided a business update and announced financial results for the fiscal year ended December 31, 2018.
Aptorum Group Limited (APM) (“Aptorum”) announced today, the appointment of Dr. Thomas Wai-yip Lee as Head of Research and Development (“Head of R&D”) and Dr. Angel Siu-yan Ng as Chief Operating Officer (“COO”) of Aptorum, effective on April 1, 2019. Dr. Thomas Lee joined Aptorum in January 2018 as the Chief Executive Officer and Chief Scientific Officer of Aptorum Therapeutics Limited, a wholly-owned subsidiary of Aptorum. Before joining Aptorum, Dr. Lee was an Assistant Professor at the School of Pharmacy at The Chinese University of Hong Kong.
Aptorum Group Limited (APM), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced that the start time for the Company’s scheduled presentation at the Barclays Global Healthcare Conference 2019 has been updated to an earlier time slot. The Company will now be presenting on Thursday, March 14th, 2019 at 10:15 a.m. ET. The conference will take place at the Loews Miami Beach Hotel in Miami Beach, Florida and will feature CEOs from industries including Biotechnology, Healthcare Facilities, Managed Care, Specialty Pharmaceuticals, U.S. Pharmaceuticals Life Science Enabling Tool and Healthcare Distribution.
Feb 25 (Reuters) - APM Automotive Holdings Bhd: * QTRLY REVENUE 382.6 MILLION RGT, QTRLY NET PROFIT 17.3 MILLION RGT * YEAR AGO QTRLY REVENUE 327.5 MILLION RGT ; YEAR AGO QTRLY NET PROFIT 13.1 MILLION ...